Analyst Price Targets — CHRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 24, 2025 1:04 pm | Ashwani Verma | UBS | $1.05 | $1.05 | TheFly | Coherus Biosciences price target lowered to $1.05 from $1.50 at UBS |
| December 5, 2024 11:50 am | Colleen Kusy | Robert W. Baird | $6.00 | $1.74 | StreetInsider | Coherus Biosciences (CHRS) PT Raised to $6 at Baird |
| November 14, 2022 7:56 am | — | J.P. Morgan | $11.00 | $7.79 | Benzinga | JP Morgan Maintains Neutral on Coherus BioSciences, Lowers Price Target to $11 |
| June 13, 2022 9:01 pm | Ashwani Verma | UBS | $7.00 | $6.19 | TheFly | Coherus Biosciences initiated with a Neutral at UBS |
Latest News for CHRS
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a…
Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript
Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise.
Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of $0.08. This compares to a loss of $0.34 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CHRS.
U.S. House Trading
No House trades found for CHRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.